









Markets
/
Stocks
/
nasdaq-mrsn
/

Mersana Therapeutics Inc

MRSN

29.080USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

145.36MMarket Cap

LossP/E TTM



Mersana Therapeutics Inc

29.080

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mersana Therapeutics Inc

Currency: USD Updated: 2026-01-05

Key Insights

Mersana Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 106 out of 401 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 33.20.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mersana Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

106 / 401

Overall Ranking

233 / 4549

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Mersana Therapeutics Inc Highlights

StrengthsRisks

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 52.35% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 40.50M.

Undervalued

The company’s latest PE is -2.07, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.36M shares, decreasing 30.94% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 88.47K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.96.

Analyst Rating

Based on 0 analysts

Current Rating

50.000

Target Price

+71.94%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-05

Its latest quarterly revenue reached 11.01M, representing a year-over-year decrease of 12.61%, while its net profit experienced a year-over-year decrease of 34.40%.

Score

Industry at a Glance

Previous score

7.76

Change



Financials

6.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.96

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.30

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Mersana Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-01-05

The current valuation score of Mersana Therapeutics Inc is 7.29, ranking 146 out of 401 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.07, which is -99.16% below the recent high of -0.02 and -0.07% above the recent low of -2.07.

Score

Industry at a Glance

Previous score

7.29

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 106/401

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-05

The current earnings forecast score of Mersana Therapeutics Inc is 6.25, ranking 343 out of 401 in the Biotechnology & Medical Research industry. The average price target is 29.00, with a high of 50.00 and a low of 27.25.

Score

Industry at a Glance

Previous score

6.25

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-05

The current price momentum score of Mersana Therapeutics Inc is 7.44, ranking 60 out of 401 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 30.53 and the support level at 27.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.09

Change

-1.65

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.953

Neutral

RSI(14)

78.054

Buy

STOCH(KDJ)(9,3,3)

53.461

Neutral

ATR(14)

0.569

High Vlolatility

CCI(14)

202.686

Overbought

Williams %R

57.456

Sell

TRIX(12,20)

0.742

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

28.886

Buy

MA10

28.946

Buy

MA20

28.689

Buy

MA50

22.492

Buy

MA100

15.236

Buy

MA200

11.900

Buy

Institutional Confidence

Currency: USD Updated: 2026-01-05

The latest institutional shareholding proportion is 65.53%, representing a quarter-over-quarter increase of 7.34%. The largest institutional shareholder is The Vanguard, holding a total of 302.55K shares, representing 6.05% of shares outstanding, with 9.96% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Alamea Verwaltungs GmbH

430.02K

+1679.24%

Schonfeld Strategic Advisors LLC

273.58K

+20.54%

683 Capital Management LLC

273.42K

+173.42%

The Vanguard Group, Inc.

Star Investors

302.55K

-1.49%

Rock Springs Capital Management LP

152.59K

-0.00%

Acadian Asset Management LLC

142.36K

+20.43%

SilverArc Capital Management, LLC

133.64K

+6.79%

BlackRock Institutional Trust Company, N.A.

93.44K

-34.36%

Renaissance Technologies LLC

Star Investors

88.47K

-22.40%

Millennium Management LLC

77.99K

-6.72%

Risk Assessment

Currency: USD Updated: 2026-01-05

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Mersana Therapeutics Inc is 2.75, ranking 210 out of 401 in the Biotechnology & Medical Research industry. The company's beta value is 0.37. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.